Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-05-31 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
关于回购股份的实施进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the progress of its share repurchase program. It details the number of shares repurchased, the proportion of total shares, prices, and total funds used. The document is short (767 characters) and focuses on the update of share buyback activity, which fits the category of a report on the company's transactions in its own shares. There is no indication that this is a full financial report or an announcement of a report publication. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS).
2018-05-31 Chinese
关于“15昆药债”2018年跟踪评级结果公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the 2018 follow-up credit rating results for the company's 2015 bond issuance. It references regulatory rules from the China Securities Regulatory Commission and the Shanghai Stock Exchange. The document states the rating results and mentions that the detailed rating report is available on the exchange website. The document length is short (645 characters) and it primarily announces the rating results rather than providing the full rating report or detailed financial data. Therefore, it is an announcement related to credit rating results, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Audit Report, or Capital/Financing Update. It is not a report publication announcement since it does not state that a report is attached or published, but rather it summarizes the rating outcome.
2018-05-29 Chinese
主体及“15昆药债”2018年度跟踪评级报告
Audit Report / Information Classification · 95% confidence The document is a detailed credit rating report issued by 东方金诚国际信用评估有限公司 for 昆药集团股份有限公司 and its bond "15 昆药债". It includes credit rating opinions, financial data from audited and unaudited financial statements, bond issuance details, macroeconomic and industry analysis, company business overview, and risk factors. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, not just an announcement or certification. It is a formal credit rating report with comprehensive financial and operational information, which aligns with the category of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or an Earnings Release (ER). It is not a regulatory filing or announcement but a standalone credit rating report with detailed financial and business analysis.
2018-05-29 Chinese
八届五十二次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details decisions made at the 52nd meeting of the 8th board, including approvals of proposals and plans, voting results, and references to other related announcements. The content focuses on board meeting decisions rather than financial results, audit opinions, or shareholder voting outcomes. It is not an annual report, earnings release, or shareholder meeting materials. The document is a formal announcement of board decisions, fitting the category of Board/Management Information (MANG). The document length is short (1259 characters), and it contains detailed board resolutions, not just a notice or report publication announcement. Therefore, the classification is MANG with high confidence.
2018-05-28 Chinese
独立董事关于公司追加2017年度、2018年度日常关联交易额度的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the company's additional daily related-party transaction limits for the years 2017 and 2018. It references regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange listing rules. The content is a formal opinion statement rather than a full report or financial statement. The document length is very short (416 characters), and it does not contain financial data or detailed analysis. It is an announcement of an opinion related to governance and compliance with listing rules, not a full governance report or audit report. Given the nature of the document as an independent director's opinion on a specific corporate matter, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2018-05-28 Chinese
关于追加2017年度、2018年度日常关联交易额度的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the increase of daily related-party transaction limits for the years 2017 and 2018. It details the nature of the related-party transactions, the parties involved, the amounts, and the compliance with stock exchange listing rules. The document is an announcement about corporate governance and related-party transactions, not a financial report or earnings release. It does not contain financial statements or earnings highlights but focuses on disclosure of related-party transactions and compliance with regulatory requirements. This fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2018-05-28 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.